These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 33150145)

  • 21. Gut microbiota contribution to hepatocellular carcinoma manifestation in non-alcoholic steatohepatitis.
    Liakina V; Strainiene S; Stundiene I; Maksimaityte V; Kazenaite E
    World J Hepatol; 2022 Jul; 14(7):1277-1290. PubMed ID: 36158907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The PPAR-microbiota-metabolic organ trilogy to fine-tune physiology.
    Oh HYP; Visvalingam V; Wahli W
    FASEB J; 2019 Sep; 33(9):9706-9730. PubMed ID: 31237779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Research progress of gut microbiota in hepatocellular carcinoma.
    Li K; Liu J; Qin X
    J Clin Lab Anal; 2022 Jul; 36(7):e24512. PubMed ID: 35719048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atypical immunometabolism and metabolic reprogramming in liver cancer: Deciphering the role of gut microbiome.
    Golonka RM; Vijay-Kumar M
    Adv Cancer Res; 2021; 149():171-255. PubMed ID: 33579424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting gut microbiota in hepatocellular carcinoma: probiotics as a novel therapy.
    Wan MLY; El-Nezami H
    Hepatobiliary Surg Nutr; 2018 Feb; 7(1):11-20. PubMed ID: 29531939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Host-Microbiota Interactions in Liver Inflammation and Cancer.
    Giraud J; Saleh M
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response.
    Delaune V; Orci LA; Lacotte S; Peloso A; Schrenzel J; Lazarevic V; Toso C
    Expert Opin Biol Ther; 2018 Oct; 18(10):1061-1071. PubMed ID: 30173562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease.
    Kallwitz ER; McLachlan A; Cotler SJ
    World J Gastroenterol; 2008 Jan; 14(1):22-8. PubMed ID: 18176957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fatty Liver Disease and Hepatocellular Carcinoma: The Pathologist's View.
    Tiniakos DG; Maurício J; Reeves HL
    Adv Exp Med Biol; 2018; 1032():55-69. PubMed ID: 30362090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows.
    Costante F; Airola C; Santopaolo F; Gasbarrini A; Pompili M; Ponziani FR
    World J Gastrointest Oncol; 2022 Sep; 14(9):1622-1636. PubMed ID: 36187401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The mechanism of dysbiosis in alcoholic liver disease leading to liver cancer.
    Méndez-Sánchez N; Valencia-Rodriguez A; Vera-Barajas A; Abenavoli L; Scarpellini E; Ponciano-Rodriguez G; Wang DQ
    Hepatoma Res; 2020; 6():. PubMed ID: 32582865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.
    Meroni M; Longo M; Dongiovanni P
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31689910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Research Progress of Fecal Microbiota Transplantation in Liver Diseases.
    Zhao Y; Gong C; Xu J; Chen D; Yang B; Chen Z; Wei L
    J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36836218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma.
    Ponziani FR; Nicoletti A; Gasbarrini A; Pompili M
    Ther Adv Med Oncol; 2019; 11():1758835919848184. PubMed ID: 31205505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of the gut microbiome in the development and progression of liver cirrhosis and hepatocellular carcinoma.
    Roderburg C; Luedde T
    Gut Microbes; 2014 Jul; 5(4):441-5. PubMed ID: 25006881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microbiota, NASH, HCC and the potential role of probiotics.
    Brandi G; De Lorenzo S; Candela M; Pantaleo MA; Bellentani S; Tovoli F; Saccoccio G; Biasco G
    Carcinogenesis; 2017 Mar; 38(3):231-240. PubMed ID: 28426878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.